TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07328581: A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

Sponsor: iCell Gene Therapeutics · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$931,500

Rescue Site Savings

+$621,000

Unlock Full NCT07328581 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07328581 Rescue Dossier →